JBS N.V. (JBS) Down 5.6% — Should I Take Profits and Move On?
JBS N.V. (JBS) is under heavy pressure this Tuesday. The stock is currently changing hands at $12.39 on the NYSE, a $0.73 decline from the prior close of $13.12. The drop deepens a slide that has been building for months. The stock now sits roughly 33.6% below its 52-week high of $18.65, a level it reached on April 10, 2026. A one-third retreat from the spring peak leaves the shares well removed from the optimism that carried them there.
Volume is running at roughly double its normal pace, with about 11.52 million shares traded so far against a 90-day average of approximately 5.68 million. Turnover at that level, with the session still open, shows investors actively repricing the stock rather than drifting with the tape.
Why JBS N.V. Price is Moving Lower
The decline traces directly to JBS's Q3 results, released after the market closed on November 9. Adjusted EPS came in at $0.16, short of $0.21 estimate and down sharply from $0.54 a year earlier. Revenue reached $22.74 billion, slightly below the $22.85 billion consensus and up just 0.6% year over year. Deeper in the report, IFRS adjusted EBITDA fell 36% to $1.18 billion, and net income dropped to $164 million from $581 million. This is a company-specific selloff. Consumer Staples peers are holding up, with Keurig Dr Pepper Inc. (KDP) up 2.08% and Pepsico, Inc. (PEP) up 1.01% on the day.
The weakness was spread across several segments, which is what makes the quarter hard to dismiss. JBS Brazil's adjusted EBITDA fell 54% to $141 million after China's 2026 import quota was filled, cutting off a key outlet for Brazilian beef. JBS USA Pork EBITDA plunged 83% to $37 million amid weaker demand and ample global supply. Pilgrim's Pride, long a dependable earnings contributor, saw EBITDA fall 40% to $462 million. When beef exports, pork, and chicken all deteriorate in the same quarter, the diversification argument that typically supports JBS offers limited protection.
The balance sheet adds to the concern. As of September 30, net leverage had risen to 3.54 times from 2.39 times a year earlier, and quarterly free cash flow turned negative at $167 million, compared with a positive $384 million in the prior-year period. The one bright spot was North American beef, where US-GAAP adjusted EBITDA swung to a $21 million profit from a $46 million loss. A recovery in that segment is a meaningful development after a long stretch of tight cattle supply, but it was far too small to offset the earnings compression and rising leverage elsewhere.
What is the JBS N.V. Rating - Should I Sell?
Weiss Ratings assigns JBS a C- rating. Current recommendation is Hold. The C- sits at the low end of Hold territory. It signals that JBS's risk/reward profile is marginal rather than broken, and the third-quarter report did little to strengthen it.
The firmer parts of the profile are operational. JBS is rated Good on the Efficiency Index, and a 13.38% ROE supports that rating for a protein processor running on a 1.22% profit margin. Meatpacking is a volume business where pennies on each pound decide the year, and JBS's ability to generate a respectable return on equity at such thin margins reflects the scale of its global plant network. The Good rating on the Solvency Index points to a balance sheet that can still carry its obligations. Even so, leverage climbing to 3.54 times and a quarter of negative free cash flow are trends that would test that rating if they persist into 2027. The 7.62% dividend yield also depends on cash generation recovering.
Where the picture becomes more difficult is growth and shareholder experience. The Weak rating on the Growth Index can look at odds with 13.82% trailing revenue growth until you consider what is happening beneath the top line. Third-quarter sales rose only 0.6%, and adjusted EPS fell by more than two-thirds year over year. Revenue expansion that does not reach earnings does little for shareholders. The Total Return and Volatility indices are both rated Weak. That is consistent with a stock trading a third below its April high and dropping more than 5% in a single session on an earnings miss. Today's reaction shows how sensitive JBS shares remain to swings in commodity spreads and export access. At a forward P/E of 12.88, the valuation is not demanding, but it does not yet reflect any confidence that the earnings decline has run its course.
Within the Consumer Staples sector, JBS is on par with Pepsico, Inc. (PEP, C-). It trails Keurig Dr Pepper Inc. (KDP, C) and sits further behind Mondelez International, Inc. (MDLZ, C+) and Ambev S.A. (ABEV, C+). Those branded beverage and snack makers benefit from pricing power and steadier margins that a commodity-exposed protein processor rarely enjoys.
About JBS N.V.
JBS N.V. (JBS) is a Consumer Staples company and one of the largest protein producers in the world. Founded in Brazil in 1953 and now listed on the NYSE, JBS processes beef, pork, chicken, lamb, and fish across operations spanning North and South America, Europe, and Australia. Its brand portfolio includes Friboi in Brazilian beef, Swift in North American and Australian meats, and Seara in Brazilian poultry, pork, and prepared foods. Through its controlling stake in Pilgrim's Pride, it also owns one of the largest chicken producers in the United States, with additional operations in Mexico and Europe.
The business serves both sides of the food chain. JBS sells fresh and frozen meat to retailers, foodservice distributors, and restaurant chains, and it has expanded into higher-margin value-added and prepared foods. Those include sausages, marinated cuts, ready-to-cook meals, and branded frozen products. That mix is designed to reduce the company's reliance on raw commodity spreads, which swing with livestock cycles, feed costs, and trade policy. Export markets, particularly in Asia, form a significant part of the demand base for its Brazilian and Australian operations.
JBS's competitive advantage rests on scale and geographic diversification. Running plants across multiple continents and protein categories lets the company shift volumes as conditions change, such as when chicken margins can cushion a downturn in beef. Its procurement leverage, logistics network, and established relationships with major global buyers are difficult for smaller processors to match. The company remains exposed to disease outbreaks, livestock supply cycles, import quotas, and environmental scrutiny of its supply chain.
Investor Outlook
JBS N.V. (JBS) carries a Weiss Rating of C- (Hold). A broad-based earnings miss, rising leverage, and negative free cash flow argue for patience over fresh buying. Investors should watch whether net leverage stabilizes from its 3.54 times level, whether Brazilian export volumes recover once China's 2027 quota cycle resets, and whether the North American beef turnaround builds enough momentum to offset weakness in pork and chicken. See full rankings of all C- rated Consumer Staples stocks inside the Weiss Stock Screener.
--